Spectral Ai Posts 32% Revenue Drop in Q2
Regulatory Milestone: Spectral Ai submitted its De Novo application to the FDA for the DeepView System in June 2025, a significant step towards commercialization of its AI-powered wound assessment device.
Financial Performance: The company reported a 32% decline in revenue year-over-year to $5.1 million, widening its net loss to $(0.31) per share, while relying heavily on government contracts for funding amid ongoing financial challenges.
Trade with 70% Backtested Accuracy
Analyst Views on MDAI
About MDAI
About the author
Spectral AI (MDAI) Third Quarter 2025 Earnings Report
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Spectral AI Secures $7.6 Million in New Growth Funding
Funding Announcement: Spectral AI, Inc. has priced a $7.6 million offering to support the growth and development of its DeepView® System, which focuses on medical diagnostics in wound care.
Share Issuance Details: The offering includes the issuance of 4,000,000 shares of common stock at $1.90 per share, along with corresponding warrants for future exercise.
Company Commitment: Chairman J. Michael DiMaio expressed confidence in securing institutional funding, emphasizing the company's commitment to advancing the DeepView System and supporting its BARDA Project BioShield contract.
About DeepView System: The DeepView System aims to provide clinicians with immediate assessments of burn wounds' healing potential, improving patient outcomes and reducing healthcare costs through algorithm-driven insights.
Spectral AI Recognized in TIME's 2025 List of Leading HealthTech Companies
Recognition of Spectral AI: Spectral AI, Inc. has been named to TIME's World's Top HealthTech Companies 2025 list, highlighting its innovative contributions to medical diagnostics in wound care.
DeepView Technology: The company's DeepView System aims to revolutionize wound management by providing predictive assessments of burn wounds, enhancing treatment decisions and potentially improving patient outcomes while reducing healthcare costs.
DeepView® System Showcased at the European Burns Association Congress
Spectral AI's Role at EBA Conference: Spectral AI showcased its advancements in burn care at the European Burns Association conference in Berlin, featuring multiple presentations on its DeepView technology, which enhances burn wound assessment through artificial intelligence and multispectral imaging.
Impact of DeepView Technology: The DeepView System aims to provide clinicians with objective assessments of burn wounds' healing potential, potentially improving patient outcomes and reducing healthcare costs, as highlighted by various studies presented at the conference.
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
Healthcare AI Market Growth: The healthcare AI market is projected to grow from $21.66 billion in 2025 to $110.61 billion by 2030, driven by a significant demand for solutions addressing an impending shortage of 11 million healthcare workers.
Avant Technologies' Vision AI Development: Avant Technologies, in collaboration with Ainnova Tech, is accelerating its FDA approval process for an AI-powered diagnostic tool that detects diabetic retinopathy, targeting diverse patient recruitment across multiple U.S. clinical sites.
Butterfly Network's Global Health Initiative: Butterfly Network is participating in a €10 million EU-funded study to deploy AI-assisted ultrasound technology for tuberculosis detection in Sub-Saharan Africa, aiming to improve diagnostic access in underserved regions.
CareCloud's Acquisition and Expansion: CareCloud has acquired Medsphere Systems Corporation, enhancing its capabilities in inpatient EHR and revenue cycle management, thereby providing scalable solutions for small and mid-sized hospitals across the U.S.
Spectral Ai Posts 32% Revenue Drop in Q2
Regulatory Milestone: Spectral Ai submitted its De Novo application to the FDA for the DeepView System in June 2025, a significant step towards commercialization of its AI-powered wound assessment device.
Financial Performance: The company reported a 32% decline in revenue year-over-year to $5.1 million, widening its net loss to $(0.31) per share, while relying heavily on government contracts for funding amid ongoing financial challenges.
Spectral AI (MDAI) Third Quarter 2025 Earnings Report
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Spectral AI Secures $7.6 Million in New Growth Funding
Funding Announcement: Spectral AI, Inc. has priced a $7.6 million offering to support the growth and development of its DeepView® System, which focuses on medical diagnostics in wound care.
Share Issuance Details: The offering includes the issuance of 4,000,000 shares of common stock at $1.90 per share, along with corresponding warrants for future exercise.
Company Commitment: Chairman J. Michael DiMaio expressed confidence in securing institutional funding, emphasizing the company's commitment to advancing the DeepView System and supporting its BARDA Project BioShield contract.
About DeepView System: The DeepView System aims to provide clinicians with immediate assessments of burn wounds' healing potential, improving patient outcomes and reducing healthcare costs through algorithm-driven insights.
Spectral AI Recognized in TIME's 2025 List of Leading HealthTech Companies
Recognition of Spectral AI: Spectral AI, Inc. has been named to TIME's World's Top HealthTech Companies 2025 list, highlighting its innovative contributions to medical diagnostics in wound care.
DeepView Technology: The company's DeepView System aims to revolutionize wound management by providing predictive assessments of burn wounds, enhancing treatment decisions and potentially improving patient outcomes while reducing healthcare costs.
DeepView® System Showcased at the European Burns Association Congress
Spectral AI's Role at EBA Conference: Spectral AI showcased its advancements in burn care at the European Burns Association conference in Berlin, featuring multiple presentations on its DeepView technology, which enhances burn wound assessment through artificial intelligence and multispectral imaging.
Impact of DeepView Technology: The DeepView System aims to provide clinicians with objective assessments of burn wounds' healing potential, potentially improving patient outcomes and reducing healthcare costs, as highlighted by various studies presented at the conference.
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
Healthcare AI Market Growth: The healthcare AI market is projected to grow from $21.66 billion in 2025 to $110.61 billion by 2030, driven by a significant demand for solutions addressing an impending shortage of 11 million healthcare workers.
Avant Technologies' Vision AI Development: Avant Technologies, in collaboration with Ainnova Tech, is accelerating its FDA approval process for an AI-powered diagnostic tool that detects diabetic retinopathy, targeting diverse patient recruitment across multiple U.S. clinical sites.
Butterfly Network's Global Health Initiative: Butterfly Network is participating in a €10 million EU-funded study to deploy AI-assisted ultrasound technology for tuberculosis detection in Sub-Saharan Africa, aiming to improve diagnostic access in underserved regions.
CareCloud's Acquisition and Expansion: CareCloud has acquired Medsphere Systems Corporation, enhancing its capabilities in inpatient EHR and revenue cycle management, thereby providing scalable solutions for small and mid-sized hospitals across the U.S.
Spectral Ai Posts 32% Revenue Drop in Q2
Regulatory Milestone: Spectral Ai submitted its De Novo application to the FDA for the DeepView System in June 2025, a significant step towards commercialization of its AI-powered wound assessment device.
Financial Performance: The company reported a 32% decline in revenue year-over-year to $5.1 million, widening its net loss to $(0.31) per share, while relying heavily on government contracts for funding amid ongoing financial challenges.
